Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: Association between elevated plasma endothelin levels and the development of ischaemic events

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 434-442

  Lozano, E ^a   Segarra, M ^a   Corbera Bellalta, M ^a   Garcia Martinez A ^a   Espigol Frigole G ^a   Pla Campo A ^a   Hernandez Rodriguez J ^a   Cid, M C ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; GLUCOCORTICOID; INTERLEUKIN 1BETA; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PREDNISONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GIANT CELL ARTERITIS; HUMAN; HUMAN CELL; IMMUNOASSAY; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPORAL ARTERY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ASPARTIC ACID ENDOPEPTIDASES; BRAIN ISCHEMIA; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIN-1; FEMALE; GENE EXPRESSION REGULATION; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1BETA; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; OPTIC NEUROPATHY, ISCHEMIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, ENDOTHELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TEMPORAL ARTERIES;

EID: 75749115591     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.105692     Document Type: Article

References (42)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
2. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;121:484-91.
3. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of proinflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giantcell arteritis. Rheumatology (Oxford) 2004;43:294-301.
4. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
5. Cid MC, Hoffman MP, Hernandez-Rodriguez J, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford) 2006;45:1356-63.
6. Rittner HL, Kaiser M, Brack A, et al. Tissue destructive macrophages in giant cell arteritis. Circ Res 1999;84:1050-8.
7. Segarra M, Sanchez M, Garcia-Martinez A, et al. Gelatinase expression and activity in giant-cell arteritis lesions. Ann Rheum Dis 2007;66:1429-35.
8. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998;41:623-33.
9. Lozano E, Segarra M, Garcia-Martinez A, et al. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant-cell arteritis. Ann Rheum Dis 2008;67:1581-8.
10. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41:26-32.
11. Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;80:355-67.
12. Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005;53:293-7.
13. Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004;83:114-22.
14. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000;79:283-92.
15. Font C, Cid MC, Coll-Vinent B, et al. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997;36:251-4.
16. Hellmann DB, Uhlfelder ML, Stone JH, et al. Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis Rheum 2003;49:819-25.
17. Crompton MR. The visual changes in temporal (giant-cell) arteritis. Report of a case with autopsy findings. Brain 1959;82:377-90.
18. Whitfield AG, Bateman M, Cooke WT. Temporal arteritis. Br J Ophthalmol 1963;47:555-66.
19. Kattah JC, Mejico L, Chrousos GA, et al. Pathologic findings in a steroid-responsive optic nerve infarct in giant-cell arteritis. Neurology 1999;53:177-80.
20. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
21. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001;41:851-76.
22. Gossl M, Lerman A. Endothelin: beyond a vasoconstrictor. Circulation 2006;113:1156-8.
23. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-40.
24. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-15.
25. Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-8.
26. Hernández-Rodríguez J, García-Martínez A, Casademont J, et al. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002;47:29-35.
27. Cid MC, Hernández-Rodríguez J, Esteban MJ, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002;106:1664-71.
28. Kleinman HK, Cid MC. Preparation of endothelial cells. In: Bonifacino JS, Dasso M, Harford JB, et al, eds. Current protocols in cell biology. New York: John Wiley and Sons, Inc, 1998:unit 2.3 pp1-4.
29. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005;43:19-29.
30. Mayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003;48:1190-9.
31. Pache M, Kaiser HJ, Haufschild T, et al. Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients. Am J Ophthalmol 2002;133:160-2.
32. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-7.
33. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
34. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417-31.
35. Hasdai D, Holmes DR Jr, Garratt KN, et al. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997;95:357-62.
36. Rondaij MG, Bierings R, Kragt A, et al. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1002-7.
37. White LR, Juul R, Skaanes KO, Aasly J. Cytokine enhancement of endothelin ET(B) receptor-mediated contraction in human temporal artery. Eur J Pharmacol 2000;406:117-22.
38. Cid MC, Garcia-Martinez A, Lozano E, et al. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007;33:819-34, vii.
39. Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003;110:1204-15.
40. Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
41. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
42. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.